R&D channel feed

Af­ter first FDA win last year, As­cendis touts a new PhI­II suc­cess in hy­poparathy­roidism

4 years ago

Sanofi's first big tri­al for top can­cer drug ends in set­back

4 years ago

Har­poon cuts bait with lead pro­gram af­ter fail­ing to find sil­ver lin­ings from AS­CO da­ta, oth­er stud­ies

4 years ago

FDA lifts a clin­i­cal hold on Se­lec­ta gene ther­a­py af­ter an­oth­er de­lay ham­pers R&D plans

4 years ago
FDA+

Mor­phoSys sends its Con­stel­la­tion drug work to Ger­many, shut­ter­ing US R&D and tak­ing a $250M hit in re­or­ga­ni­za­tion

4 years ago
Deals

Not an an­ti-ag­ing play? Al­tos’ top sci­en­tist says they can pre­vent ag­ing in 20 years

4 years ago
Startups

Look­ing to bat­tle ri­vals in a big mar­ket, Ab­b­Vie is head­ed to the FDA af­ter clear­ing a PhI­II hur­dle for chron­ic mi­graine

4 years ago

Mod­er­na plays Big Phar­ma ball with CEO pay, push­ing bil­lion­aire Ban­cel in­to the ma­jor leagues

4 years ago
People

A trio of amy­loid-tar­get­ed Alzheimer's drugs will soon see key re­sults, but an an­a­lyst pre­dicts on­ly 50-50 odds for one

4 years ago
Pharma

Sanofi sets up a ti­tle fight with Roche in he­mo­phil­ia A — pro­vid­ed gene ther­a­pies don't beat them to the punch

4 years ago

FDA's on­col­o­gy ad­comm to re­view PI3K in­hibitors in blood can­cers in April

4 years ago
FDA+

Lu­l­ule­mon founder com­mits $100M to cure his rare dis­ease

4 years ago
Discovery

Big Phar­ma vet­er­an Karin Shana­han re­unites with Bris­tol My­er­s' sup­ply team af­ter 12 years apart

4 years ago

Re­al world da­ta and FDA: Drug­mak­ers seek more clar­i­ty on reg­istry guid­ance

4 years ago
FDA+

Nasal spray mak­er clinch­es first PhI­II win it needs to reach a much, much big­ger mar­ket

4 years ago

Rac­ing Bay­er, Astel­las puts the fi­nal PhI­II slide in­to its FDA/EMA pitch

4 years ago

Gilead draws harsh re­views as PhI­II for $21B Im­munomedics drug un­der­whelms Wall Street

4 years ago

Sanofi pe­ti­tions FDA over 'mis­lead­ing' la­bel for ri­val flu vac­cine that failed to con­firm ben­e­fit

4 years ago
Pharma

With all eyes on Chi­nese-on­ly on­col­o­gy da­ta, Co­herus and Jun­shi un­cork win for PD-1 drug in esophageal can­cer

4 years ago
China

With new Alzheimer's pre­ven­tion tri­al, Roche and Genen­tech may put amy­loid hy­poth­e­sis to ul­ti­mate test

4 years ago

Af­ter buy­ing out Flex­ion for $450M, Paci­ra qui­et­ly lays off 110 of its em­ploy­ees

4 years ago
People

Rus­si­a's war in Ukraine is now de­lay­ing da­ta read­outs, as Tri­ci­da says its sec­ond-chance tri­al needs more time

4 years ago

Full da­ta for Sanofi and As­traZeneca's new RSV an­ti­body raise ques­tions about just how wide­ly it will be used

4 years ago

Up­dat­ed: Weak­er Omi­cron vari­ant is great news for the world, but bad news for Covid-re­lat­ed clin­i­cal tri­als

4 years ago
Coronavirus
First page Previous page 144145146147148149150 Next page Last page
A service from the Financial Times